121 related articles for article (PubMed ID: 29578150)
1. Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis.
Wu GJ; Bao JS; Yue ZJ; Zeng FC; Cen S; Tang ZY; Kang XL
J Cancer Res Ther; 2018; 14(Supplement):S54-S59. PubMed ID: 29578150
[TBL] [Abstract][Full Text] [Related]
2. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer.
Durkan GC; Nutt JE; Marsh C; Rajjayabun PH; Robinson MC; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2003 Jul; 9(7):2576-82. PubMed ID: 12855633
[TBL] [Abstract][Full Text] [Related]
3. Elevated matrix metalloproteinase-9 expression may contribute to the pathogenesis of bladder cancer.
Zeng FC; Cen S; Tang ZY; Kang XL
Oncol Lett; 2016 Mar; 11(3):2213-2222. PubMed ID: 26998151
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer.
Reis ST; Leite KR; Piovesan LF; Pontes-Junior J; Viana NI; Abe DK; Crippa A; Moura CM; Adonias SP; Srougi M; Dall'Oglio MF
BMC Urol; 2012 Jun; 12():18. PubMed ID: 22695075
[TBL] [Abstract][Full Text] [Related]
5. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer.
Fouad H; Salem H; Ellakwa DE; Abdel-Hamid M
J Biochem Mol Toxicol; 2019 Apr; 33(4):e22275. PubMed ID: 30548095
[TBL] [Abstract][Full Text] [Related]
6. MMP, VEGF and TIMP as prognostic factors in recurring bladder cancer.
Wieczorek E; Jablonowski Z; Tomasik B; Konecki T; Jablonska E; Gromadzinska J; Fendler W; Sosnowski M; Wasowicz W; Reszka E
Clin Biochem; 2015 Dec; 48(18):1235-40. PubMed ID: 26197083
[TBL] [Abstract][Full Text] [Related]
7. High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer.
Qin Z; Wang Y; Tang J; Zhang L; Li R; Xue J; Han P; Wang W; Qin C; Xing Q; Yang J; Zhang W
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30054424
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of matrix metalloproteinase 2 protein expression in patients with renal cell carcinoma: A case-control study and meta-analysis.
Liu Q; Zhang GW; Zhu CY; Wei JX; Tian X; Li Y; Li XD
Cancer Biomark; 2016; 16(2):281-9. PubMed ID: 26756619
[TBL] [Abstract][Full Text] [Related]
9. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
10. The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.
Ramón de Fata F; Ferruelo A; Andrés G; Gimbernat H; Sánchez-Chapado M; Angulo JC
Actas Urol Esp; 2013 Sep; 37(8):480-8. PubMed ID: 23916137
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
12. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
Di Carlo A; Terracciano D; Mariano A; Macchia V
Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
[TBL] [Abstract][Full Text] [Related]
13. [Expressions of MMP-2 and COX-2 mRNA in bladder transitional cell carcinoma and their correlation].
Zhang HP; Yu B; Zheng XD; Hu HJ; Gao ZB; Li L; Zhou LF
Zhonghua Nan Ke Xue; 2008 Nov; 14(11):1011-4. PubMed ID: 19102503
[TBL] [Abstract][Full Text] [Related]
14. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
15. Association of Matrix Metalloproteinase-7 Genotypes with the Risk of Bladder Cancer.
Liao CH; Chang WS; Tsai CW; Hu PS; Wu HC; Hsu SW; Chen GL; Yueh TC; Shen TC; Hsia TC; Bau DT
In Vivo; 2018; 32(5):1045-1050. PubMed ID: 30388078
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
Candido S; Di Maso M; Serraino D; McCubrey JA; Bortolus R; Zanin M; Battiston M; Salemi R; Libra M; Polesel J
Tumour Biol; 2016 Jul; 37(7):9855-63. PubMed ID: 26810191
[TBL] [Abstract][Full Text] [Related]
17. An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines.
You J; Madigan MC; Rowe A; Sajinovic M; Russell PJ; Jackson P
Urol Oncol; 2012; 30(4):502-8. PubMed ID: 20864363
[TBL] [Abstract][Full Text] [Related]
18. Preoperative levels of matrix metalloproteinase-7 and -9 and tissue inhibitor of matrix metalloproteinase-1 relation to pathologic parameters in bladder carcinoma patients.
Gunes M; Kemik AS; Pirincci N; Gecit I; Taken K; Yuksel MB; Kaba M; Eryilmaz R
Asian Pac J Cancer Prev; 2013; 14(2):873-6. PubMed ID: 23621254
[TBL] [Abstract][Full Text] [Related]
19. Expression and Clinical Significance of MMP-28 in Bladder Cancer.
Wang H; Wu JX; Chen XP; Zhang Q; Wei HB; Wang HJ; Yang X; Zhang DH
Technol Cancer Res Treat; 2020; 19():1533033820974017. PubMed ID: 33191847
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis.
Merdad A; Karim S; Schulten HJ; Dallol A; Buhmeida A; Al-Thubaity F; Gari MA; Chaudhary AG; Abuzenadah AM; Al-Qahtani MH
Anticancer Res; 2014 Mar; 34(3):1355-66. PubMed ID: 24596383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
